Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529017 | 0.89 | NPC1 (0.52) | KDRBTKFLT3MEN1KMT2A | |
| SCHEMBL5526278 | 0.79 | MEN1 (0.53) | KDM1AMEN1USP2MAPTHTT | |
| SCHEMBL28000258 | 0.73 | HTR2A (0.64) | KDRKITPDGFRAHTR2CCASP3 | |
| SCHEMBL3434704 | 0.71 | NPC1 (0.55) | KDRBTKMEN1KMT2A | |
| SCHEMBL30577378 | 0.71 | HTR1D (0.60) | BTKCASP3CASP7HTR2AHTR1D | |
| SCHEMBL22410915 | 0.70 | HTR2A (0.59) | HTR2CCASP3CASP7HTR2AHTR1D | |
| SCHEMBL77343 | 0.69 | NPC1 (0.47) | KDRBTKFLT3MEN1MAPT | |
| SCHEMBL2536426 | 0.68 | NPC1 (0.54) | KDRBTKMEN1USP2MAPT | |
| SCHEMBL3788577 | 0.68 | BTK (0.57) | KDRBTKMEN1KMT2A | |
| SCHEMBL29521619 | 0.68 | HTR2A (0.52) | HTR2CCASP3CASP7HTR2AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | MAP3K1, MAP3K3, MAP3K5 | KDR 422/4885KIT 282/4885PDGFRA 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.